×
S&P 500   3,828.21 (+1.13%)
DOW   31,117.78 (+1.11%)
QQQ   281.20 (+0.33%)
AAPL   138.54 (+1.33%)
MSFT   259.36 (+0.99%)
META   159.82 (-0.89%)
GOOGL   2,170.65 (-0.40%)
AMZN   109.53 (+3.13%)
TSLA   677.28 (+0.57%)
NVDA   145.39 (-4.09%)
NIO   21.39 (-1.52%)
BABA   116.07 (+2.10%)
AMD   73.67 (-3.66%)
MU   53.45 (-3.31%)
CGC   2.81 (-1.40%)
T   21.37 (+1.96%)
GE   63.71 (+0.06%)
F   11.31 (+1.62%)
DIS   96.01 (+1.71%)
AMC   13.44 (-0.81%)
PFE   52.28 (-0.29%)
PYPL   71.30 (+2.09%)
NFLX   179.80 (+2.82%)
S&P 500   3,828.21 (+1.13%)
DOW   31,117.78 (+1.11%)
QQQ   281.20 (+0.33%)
AAPL   138.54 (+1.33%)
MSFT   259.36 (+0.99%)
META   159.82 (-0.89%)
GOOGL   2,170.65 (-0.40%)
AMZN   109.53 (+3.13%)
TSLA   677.28 (+0.57%)
NVDA   145.39 (-4.09%)
NIO   21.39 (-1.52%)
BABA   116.07 (+2.10%)
AMD   73.67 (-3.66%)
MU   53.45 (-3.31%)
CGC   2.81 (-1.40%)
T   21.37 (+1.96%)
GE   63.71 (+0.06%)
F   11.31 (+1.62%)
DIS   96.01 (+1.71%)
AMC   13.44 (-0.81%)
PFE   52.28 (-0.29%)
PYPL   71.30 (+2.09%)
NFLX   179.80 (+2.82%)
S&P 500   3,828.21 (+1.13%)
DOW   31,117.78 (+1.11%)
QQQ   281.20 (+0.33%)
AAPL   138.54 (+1.33%)
MSFT   259.36 (+0.99%)
META   159.82 (-0.89%)
GOOGL   2,170.65 (-0.40%)
AMZN   109.53 (+3.13%)
TSLA   677.28 (+0.57%)
NVDA   145.39 (-4.09%)
NIO   21.39 (-1.52%)
BABA   116.07 (+2.10%)
AMD   73.67 (-3.66%)
MU   53.45 (-3.31%)
CGC   2.81 (-1.40%)
T   21.37 (+1.96%)
GE   63.71 (+0.06%)
F   11.31 (+1.62%)
DIS   96.01 (+1.71%)
AMC   13.44 (-0.81%)
PFE   52.28 (-0.29%)
PYPL   71.30 (+2.09%)
NFLX   179.80 (+2.82%)
S&P 500   3,828.21 (+1.13%)
DOW   31,117.78 (+1.11%)
QQQ   281.20 (+0.33%)
AAPL   138.54 (+1.33%)
MSFT   259.36 (+0.99%)
META   159.82 (-0.89%)
GOOGL   2,170.65 (-0.40%)
AMZN   109.53 (+3.13%)
TSLA   677.28 (+0.57%)
NVDA   145.39 (-4.09%)
NIO   21.39 (-1.52%)
BABA   116.07 (+2.10%)
AMD   73.67 (-3.66%)
MU   53.45 (-3.31%)
CGC   2.81 (-1.40%)
T   21.37 (+1.96%)
GE   63.71 (+0.06%)
F   11.31 (+1.62%)
DIS   96.01 (+1.71%)
AMC   13.44 (-0.81%)
PFE   52.28 (-0.29%)
PYPL   71.30 (+2.09%)
NFLX   179.80 (+2.82%)
LON:MXCT

MaxCyte Share Forecast, Price & News

GBX 387.50
+7.50 (+1.97%)
(As of 07/1/2022 05:06 PM ET)
Add
Compare
Today's Range
370
390
50-Day Range
292
450
52-Week Range
280
1,235
Volume
11,462 shs
Average Volume
70,884 shs
Market Capitalization
£393.47 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
30 days | 90 days | 365 days | Advanced Chart

Receive MXCT Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for MaxCyte and its competitors with MarketBeat's FREE daily newsletter.

MXCT Stock Forecast (MarketRank)

Overall MarketRank

0.91 out of 5 stars

Analyst Opinion: 0.0Community Rank: 4.5Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -
MaxCyte logo

About MaxCyte (LON:MXCT)

MaxCyte, Inc., a global life sciences company, engages in the discovery, development, and commercialization of next-generation cell therapies. Its products include ExPERT ATx, a static electroporation instrument for small to medium scale transfection; ExPERT STx, a flow electroporation for protein production and drug development, as well as expression of therapeutic targets for cell-based assays; ExPERT GTx, a flow electroporation for large scale transfection in therapeutic applications; and ExPERT VLx for very large volume cell-engineering. The company also provides disposable processing assemblies (PAs) to process and electroporate cells; and accessories supporting PAs, such as electroporation buffer solution and software protocols. The company was incorporated in 1998 and is headquartered in Gaithersburg, Maryland.

MXCT Stock News Headlines

See More Headlines

Industry, Sector and Symbol

Industry
Diagnostics & Research
Sub-Industry
N/A
Sector
Medical
CIK
N/A
Fax
N/A
Employees
84
Year Founded
N/A

Profitability

Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
£38.99 million
Cash Flow
GBX 240.95 per share
Book Value
GBX 258.30 per share

Miscellaneous

Free Float
N/A
Market Cap
£393.47 million
Optionable
Not Optionable
Beta
N/A














MaxCyte Frequently Asked Questions

How has MaxCyte's stock performed in 2022?

MaxCyte's stock was trading at GBX 755 at the start of the year. Since then, MXCT shares have decreased by 48.7% and is now trading at GBX 387.50.
View the best growth stocks for 2022 here
.

Who are MaxCyte's key executives?

MaxCyte's management team includes the following people:
  • Mr. Douglas Arthur Doerfler, Founder, Pres, CEO & Exec. Director (Age 66, Pay $1.39M)
  • Mr. Ronald Evan Holtz CPA, Ph.D., Chief Financial Officer (Age 64, Pay $649.38k)
  • Dr. J. Stark Thompson Ph.D., Consultant (Age 80, Pay $84.71k)
  • Dr. Cenk Sumen, Chief Scientific Officer (Age 49)
  • Mr. Sean Menarguez, Director of Investor Relations
  • Mr. Maher Masoud, Exec. VP, Gen. Counsel & Sec. (Age 47)
  • Mr. Thomas Michael Ross, Exec. VP of Global Sales (Age 61)
  • Mr. Kevin Gutshall, VP of Strategy & Corp. Devel.
  • Dr. James Brady Ph.D., Sr. VP of Technical Applications & Customer Support
  • Dr. Sarah Haecker Meeks Ph.D., Sr. VP of Bus. Devel.

What other stocks do shareholders of MaxCyte own?

Based on aggregate information from My MarketBeat watchlists, some companies that other MaxCyte investors own include boohoo group (BOO), Juno Therapeutics (JUNO), (ATE), Astrotech (ASTC), Arcturus Therapeutics (ARCT), (AQB), Aptose Biosciences (APTO), Appili Therapeutics (APLIF), Argan (AGX) and Applied Genetic Technologies (AGTC).

What is MaxCyte's stock symbol?

MaxCyte trades on the London Stock Exchange (LON) under the ticker symbol "MXCT."

How do I buy shares of MaxCyte?

Shares of MXCT and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.
Compare Top Brokerages Here.

What is MaxCyte's stock price today?

One share of MXCT stock can currently be purchased for approximately GBX 387.50.

How much money does MaxCyte make?

MaxCyte (LON:MXCT) has a market capitalization of £393.47 million and generates £38.99 million in revenue each year.

How many employees does MaxCyte have?

MaxCyte employs 84 workers across the globe.

How can I contact MaxCyte?

MaxCyte's mailing address is 22 Firstfield Rd Ste 110, GAITHERSBURG, MD 20878-1795, United States. The official website for MaxCyte is www.maxcyte.com. The company can be reached via phone at +1-301-9441700.

This page (LON:MXCT) was last updated on 7/1/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer.